{"id":"atorvastatin-omeprazole","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Gastrointestinal disturbance"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Atorvastatin inhibits HMG-CoA reductase to reduce LDL cholesterol and cardiovascular risk, while omeprazole suppresses gastric acid secretion by blocking the H+/K+-ATPase pump. The combination is designed to provide cardiovascular protection while reducing gastrointestinal side effects or acid-related conditions that may occur with statin therapy.","oneSentence":"This is a fixed-dose combination of atorvastatin (a statin that lowers cholesterol) and omeprazole (a proton pump inhibitor that reduces stomach acid).","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:42:54.074Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypercholesterolemia with concurrent need for gastric acid suppression"},{"name":"Cardiovascular risk reduction in patients requiring proton pump inhibitor therapy"}]},"trialDetails":[{"nctId":"NCT06690164","phase":"PHASE4","title":"Study on the Effect of Atorvastatin Co-administered With Omeprazole on Statin Lactone","status":"RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2025-06-12","conditions":"Metabolite","enrollment":78},{"nctId":"NCT05925140","phase":"PHASE1","title":"LUSZ Treatment Efficacy in Hospitalized COVID-19 Patients","status":"UNKNOWN","sponsor":"Lebanese University","startDate":"2020-03-28","conditions":"COVID-19, Hospitalized COVID-19 Patients","enrollment":1000},{"nctId":"NCT05893849","phase":"","title":"Pharmacokinetics of Clinical Probes and Characteristics of Endogenous Biomarker in Chinese Older Adults","status":"UNKNOWN","sponsor":"Peking University Third Hospital","startDate":"2023-03-28","conditions":"Aging","enrollment":624},{"nctId":"NCT04333407","phase":"NA","title":"Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial.","status":"TERMINATED","sponsor":"Imperial College London","startDate":"2020-04-03","conditions":"COVID-19","enrollment":320},{"nctId":"NCT05334108","phase":"PHASE1","title":"Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates for Drug Metabolism and Transport","status":"COMPLETED","sponsor":"Emalex Biosciences Inc.","startDate":"2022-04-26","conditions":"Drug Interaction","enrollment":56},{"nctId":"NCT03709355","phase":"PHASE1","title":"Pharmacokinetics Study to Evaluate Drug-Drug Interactions and Safety of Elpida® in Co-Administration With Other Drugs","status":"COMPLETED","sponsor":"Viriom","startDate":"2018-11-14","conditions":"HIV-1-infection","enrollment":56},{"nctId":"NCT04764851","phase":"PHASE1","title":"Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates","status":"TERMINATED","sponsor":"Emalex Biosciences Inc.","startDate":"2021-02-18","conditions":"Drug-Interactions","enrollment":30},{"nctId":"NCT00930670","phase":"PHASE4","title":"Evaluation of the Influence of Statins and Proton Pump Inhibitors on Clopidogrel Antiplatelet Effects","status":"COMPLETED","sponsor":"Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec","startDate":"2009-06","conditions":"Coronary Artery Disease","enrollment":320}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ASTHENIA"},{"count":1,"reaction":"BLOOD SODIUM DECREASED"},{"count":1,"reaction":"GRAND MAL CONVULSION"},{"count":1,"reaction":"MALAISE"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Atorvastatin-omeprazole","genericName":"Atorvastatin-omeprazole","companyName":"Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec","companyId":"centre-de-recherche-de-l-institut-universitaire-de-cardiologie-et-de-pneumologie","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a fixed-dose combination of atorvastatin (a statin that lowers cholesterol) and omeprazole (a proton pump inhibitor that reduces stomach acid). Used for Hypercholesterolemia with concurrent need for gastric acid suppression, Cardiovascular risk reduction in patients requiring proton pump inhibitor therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}